Conditions & Recovery · ScienceDaily Cancer · October 10, 2026

Bowel cancer “melted away” after immunotherapy, then stayed away

A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patients with a specific genetic form of bowel cancer received pembrolizumab for up to nine weeks before surgery instead of the usual post-surgery chemotherapy. After nearly three years of follow-up, none of the patients had ex

Originally published by ScienceDaily Cancer. We curate and add context; they did the reporting.

Related learning